Shopping Cart
Remove All
Your shopping cart is currently empty
Pidilizumab (CT-011) is a humanized monoclonal antibody that modulates anti-tumor immune responses by targeting the PD-1 receptor and the Notch ligand DLL1. It enhances the activity of T cells and natural killer (NK) cells, demonstrating significant clinical potential in the study of hematologic malignancies, particularly follicular lymphoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Pidilizumab (CT-011) is a humanized monoclonal antibody that modulates anti-tumor immune responses by targeting the PD-1 receptor and the Notch ligand DLL1. It enhances the activity of T cells and natural killer (NK) cells, demonstrating significant clinical potential in the study of hematologic malignancies, particularly follicular lymphoma. |
| Synonyms | MDV9300, CT-011 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-1 |
| Cas No. | 1036730-42-3 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.